A citation-based method for searching scientific literature

Maria Isabel Del Olmo-García, David Hervás Marín, Jana Caudet Esteban, Antonio Ballesteros Martin-Portugués, Alba Cerveró Rubio, Miguel Angel Arnau Vives, Ana Catalá Gregori, Maite Penalba Martínez, Juan Francisco Merino-Torres. J Int Med Res 2020
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Wei Ren Chen, Shun Ying Hu, Yun Dai Chen, Ying Zhang, Geng Qian, Jing Wang, Jun Jie Yang, Zhi Feng Wang, Feng Tian, Qing Xiu Ning. Am Heart J 2015
66
100

The population burden of heart failure attributable to modifiable risk factors: the ARIC (Atherosclerosis Risk in Communities) study.
Christy L Avery, Laura R Loehr, Christopher Baggett, Patricia P Chang, Anna M Kucharska-Newton, Kunihiro Matsushita, Wayne D Rosamond, Gerardo Heiss. J Am Coll Cardiol 2012
67
100

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
Steven P Marso, Florian M M Baeres, Stephen C Bain, Bryan Goldman, Mansoor Husain, Michael A Nauck, Neil R Poulter, Richard E Pratley, Anne Bloch Thomsen, John B Buse. J Am Coll Cardiol 2020
13
100

Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.
Da-Ya Yang, Xin He, Hui-Wei Liang, Shao-Zhao Zhang, Xiang-Bin Zhong, Chu-Fan Luo, Zhi-Min Du, Jian-Gui He, Xiao-Dong Zhuang, Xin-Xue Liao. Cardiovasc Diabetol 2019
11
100

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study.
Matthew J McQueen, Steven Hawken, Xingyu Wang, Stephanie Ounpuu, Allan Sniderman, Jeffrey Probstfield, Krisela Steyn, John E Sanderson, Mohammad Hasani, Emilia Volkova,[...]. Lancet 2008
502
100

Liraglutide and Glycaemic Outcomes in the LEADER Trial.
Bernard Zinman, Michael A Nauck, Heidrun Bosch-Traberg, Helle Frimer-Larsen, David D Ørsted, John B Buse. Diabetes Ther 2018
8
100

Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction.
Wei-Ren Chen, Xue-Qin Shen, Ying Zhang, Yun-Dai Chen, Shun-Ying Hu, Geng Qian, Jing Wang, Jun-Jie Yang, Zhi-Feng Wang, Feng Tian. Endocrine 2016
44
100

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. Int J Surg 2010
100

Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.
G T Russo, A M Labate, A Giandalia, E L Romeo, P Villari, A Alibrandi, G Perdichizzi, D Cucinotta. J Endocrinol Invest 2015
26
100

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
B Mihaylova, J Emberson, L Blackwell, A Keech, J Simes, E H Barnes, M Voysey, A Gray, R Collins, C Baigent. Lancet 2012
100

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
642
100

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
B Wang, J Zhong, H Lin, Z Zhao, Z Yan, H He, Y Ni, D Liu, Z Zhu. Diabetes Obes Metab 2013
125
100

Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data.
Edward W Gregg, Yiling J Cheng, Meera Srinivasan, Ji Lin, Linda S Geiss, Ann L Albright, Giuseppina Imperatore. Lancet 2018
147
100


Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
100

National Lipid Association Annual Summary of Clinical Lipidology 2016.
Harold E Bays, Peter H Jones, Carl E Orringer, W Virgil Brown, Terry A Jacobson. J Clin Lipidol 2016
60
100

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
N Sarwar, P Gao, S R Kondapally Seshasai, R Gobin, S Kaptoge, E Di Angelantonio, E Ingelsson, D A Lawlor, E Selvin, M Stampfer,[...]. Lancet 2010
100

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.
Preman Kumarathurai, Christian Anholm, Olav W Nielsen, Ole P Kristiansen, Jens Mølvig, Sten Madsbad, Steen B Haugaard, Ahmad Sajadieh. Cardiovasc Diabetol 2016
35
100


Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Tina Vilsbøll, Mikkel Christensen, Anders E Junker, Filip K Knop, Lise Lotte Gluud. BMJ 2012
505
100

A Systematic Review and Meta-Analysis of Controlled Trials on the Effects of Statin and Fibrate Therapies on Plasma Homocysteine Levels.
Amirhossein Sahebkar, Matteo Pirro, Željko Reiner, Arrigo Cicero, Gianna Ferretti, Mario Simental-Mendía, Luis E Simental-Mendía. Curr Med Chem 2016
14
100

Cardioprotective Properties of HDL: Structural and Functional Considerations.
Eleni Pappa, Moses S Elisaf, Christina Kostara, Eleni Bairaktari, Vasilis K Tsimihodimos. Curr Med Chem 2020
13
100

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
392
100


Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012.
Andy Menke, Sarah Casagrande, Linda Geiss, Catherine C Cowie. JAMA 2015
100

Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
Olivia R Ghosh-Swaby, Shaun G Goodman, Lawrence A Leiter, Alice Cheng, Kim A Connelly, David Fitchett, Peter Jüni, Michael E Farkouh, Jacob A Udell. Lancet Diabetes Endocrinol 2020
37
100

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
Preman Kumarathurai, Christian Anholm, Andreas Fabricius-Bjerre, Olav W Nielsen, Ole Kristiansen, Sten Madsbad, Steen B Haugaard, Ahmad Sajadieh. J Hypertens 2017
24
100

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure.
Mads Halbirk, Helene Nørrelund, Niels Møller, Jens Juul Holst, Ole Schmitz, Roni Nielsen, Jens Erik Nielsen-Kudsk, Søren Steen Nielsen, Torsten Toftegaard Nielsen, Hans Eiskjaer,[...]. Am J Physiol Heart Circ Physiol 2010
115
100

Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study.
Ron C Hoogeveen, John W Gaubatz, Wensheng Sun, Rhiannon C Dodge, Jacy R Crosby, Jennifer Jiang, David Couper, Salim S Virani, Sekar Kathiresan, Eric Boerwinkle,[...]. Arterioscler Thromb Vasc Biol 2014
224
100


Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Thomas Nyström, Mark K Gutniak, Qimin Zhang, Fan Zhang, Jens Juul Holst, Bo Ahrén, Ake Sjöholm. Am J Physiol Endocrinol Metab 2004
482
100

Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
Michael C Honigberg, Lee-Shing Chang, Darren K McGuire, Jorge Plutzky, Vanita R Aroda, Muthiah Vaduganathan. JAMA Cardiol 2020
11
100

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
Anders Jorsal, Caroline Kistorp, Pernille Holmager, Rasmus Stilling Tougaard, Roni Nielsen, Anja Hänselmann, Brian Nilsson, Jacob Eifer Møller, Jakob Hjort, Jon Rasmussen,[...]. Eur J Heart Fail 2017
178
100


Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
David Fitchett, Silvio E Inzucchi, Christopher P Cannon, Darren K McGuire, Benjamin M Scirica, Odd Erik Johansen, Steven Sambevski, Stefan Kaspers, Egon Pfarr, Jyothis T George,[...]. Circulation 2019
76
100

A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure.
Mohammed Munaf, Pierpaolo Pellicori, Victoria Allgar, Kenneth Wong. Int J Pept 2012
21
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.